COLLPLANT BIOTECH. IS-01 Total Assets
COLLPLANT BIOTECH. IS-01 total assets. Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) holds total assets worth €9.18 Million EUR (≈ $10.74 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is COLLPLANT BIOTECH. IS-01 worth for the company's overall valuation and market capitalisation.
Total Assets of COLLPLANT BIOTECH. IS-01 (2021–2025)
Total assets of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. This chart illustrates how COLLPLANT BIOTECH. IS-01's total assets have evolved over time, based on quarterly financial data. See COLLPLANT BIOTECH. IS-01 stock price for real-time trading data and today's change.
COLLPLANT BIOTECH. IS-01 - Asset Composition Analysis
COLLPLANT BIOTECH. IS-01 Total Assets Breakdown (December 2025)
COLLPLANT BIOTECH. IS-01 total assets breakdown as of December 2025. COLLPLANT BIOTECH. IS-01's total assets of €9.18 Million consist of 62.6% current assets and 37.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 51.8% |
| Accounts Receivable | €1.00K | 0.0% |
| Inventory | €573.00K | 5.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore COLLPLANT BIOTECH. IS-01 (CPT) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: COLLPLANT BIOTECH. IS-01's current assets represent 62.6% of total assets in 2025, a decrease from 88.0% in 2021.
- Cash Position: Cash and equivalents constituted 51.8% of total assets in 2025, up from 25.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 5.3% of total assets.
COLLPLANT BIOTECH. IS-01 Competitors by Total Assets
Key competitors of COLLPLANT BIOTECH. IS-01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
COLLPLANT BIOTECH. IS-01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 4.48 | 5.38 |
| Quick Ratio | 1.99 | 4.23 | 5.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.10 Million | €9.39 Million | €13.43 Million |
COLLPLANT BIOTECH. IS-01 - Advanced Valuation Insights
This section examines the relationship between COLLPLANT BIOTECH. IS-01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | -42.4% |
| Total Assets | €10.79 Million |
| Market Capitalization | $5.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values COLLPLANT BIOTECH. IS-01's assets below their book value (0.51x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: COLLPLANT BIOTECH. IS-01's assets decreased by 42.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual total assets of COLLPLANT BIOTECH. IS-01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €10.79 Million ≈ $12.61 Million |
-42.36% |
| 2024-12-31 | €18.71 Million ≈ $21.87 Million |
-45.17% |
| 2023-12-31 | €34.13 Million ≈ $39.90 Million |
-9.64% |
| 2022-12-31 | €37.77 Million ≈ $44.15 Million |
-26.27% |
| 2021-12-31 | €51.22 Million ≈ $59.89 Million |
-- |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more